DOI:
10.1055/s-00029028
Journal of Pediatric Infectious Diseases
LinksClose Window
References
Hafkin J, Frias M, DeLeon A. , et al.
Long-term safety, tolerability, and pharmacokinetics of delamanid in pediatric MDR-TB patients, ages 12–17 years.
Abstract presented at: 46th Union World Conference on Lung Health, 2015 Dec 2–6, 2015 ; Cape Town, South Africa
Access:
We do not assume any responsibility for the contents of the web pages of other providers.